bioAffinity Technologies, Inc. announced that the U.S. Patent and Trademark Office (USPTO) has provided a Notice of Allowance for a patent application titled “Porphyrin Compounds and Compositions Useful for Treating Cancer” for the targeted delivery of novel cancer treatments. A Notice of Allowance is issued after the USPTO makes a determination that a patent should be granted for the claimed invention. The U.S. patent will issue to the Company's wholly owned subsidiary OncoSelect and grant protection to 2037.

Research related to the Company's non-invasive lung cancer diagnostic CyPath® Lung led to the discoveries being developed to treat cancer including using porphyrins conjugated with oncological drugs for more targeted delivery with fewer unwanted treatment-associated side effects. Porphyrins, such as the synthetic molecule TCPP used in CyPath® Lung, preferentially enter cancer cells and may lead to greater uptake of chemotherapeutics attached to the porphyrin with less impact on healthy cells. bioAffinity Technologies is advancing its therapeutic assets with the intent to license its products for clinical development.

Its subsidiary OncoSelect holds patents to Porphyrin Compounds and Compositions Useful for Treating Cancer in Australia, China and Mexico and pending applications in Canada, the European Patent Office, Hong Kong, India and Japan.